A First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes Mellitus
Arrowhead Pharmaceuticals · Obesity · Diabetes Mellitus, Type 2
Phase 1 / Phase 2
Recruiting
150
2026-07
Industry sponsor intelligence
Arrowhead PharmaceuticalsClinical Pipeline.
Lead-sponsor view of Arrowhead Pharmaceuticals's indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 2
- Recruiting
- 2
- Active
- 0
- Completed
- 0
- Results posted
- 0
- Avg enrollment
- 165
Pipeline overview
Programs by phase and activity.
Velocity
Arrowhead Pharmaceuticals trials by start year
Study start year · indexed snapshot
Development
Trials by phase
4phase labels
Early Phase 10
Phase 12
Phase 22
Phase 30
Phase 40
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Tirzepatide → | 2 | 2 | 2 | 0 | 0 | 2 |
Active peptide trials
In motion now.
NCT IDStudyPhase / statusEnrollmentUpdated
A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus
Arrowhead Pharmaceuticals · Obesity
Phase 1 / Phase 2
Recruiting
180
2026-06
Completed trials
Finished registry records.
No studies in this snapshot.
Search sponsor records
All Arrowhead Pharmaceuticals studies.
This page groups studies where Arrowhead Pharmaceuticals is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
2 matching studies
Last registry update first